These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31615476)

  • 1. Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study.
    Donnelly DW; Vis LC; Kearney T; Sharp L; Bennett D; Wilding S; Downing A; Wright P; Watson E; Wagland R; Cross WR; Mason MD; Siesling S; van Manen JG; Glaser AW; Gavin A
    BMC Cancer; 2019 Oct; 19(1):947. PubMed ID: 31615476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom.
    Donnelly DW; Gavin A; Downing A; Hounsome L; Kearney T; McNair E; Allan D; Huws DW; Wright P; Selby PJ; Kind P; Watson E; Wagland R; Wilding S; Butcher H; Mottram R; Allen M; McSorley O; Sharp L; Mason MD; Cross WR; Catto JWF; Glaser AW
    Eur Urol; 2019 Aug; 76(2):228-237. PubMed ID: 31060822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.
    Downing A; Wright P; Hounsome L; Selby P; Wilding S; Watson E; Wagland R; Kind P; Donnelly DW; Butcher H; Catto JWF; Cross W; Mason M; Sharp L; Weller D; Velikova G; McCaughan E; Mottram R; Allen M; Kearney T; McSorley O; Huws DW; Brewster DH; McNair E; Gavin A; Glaser AW
    Lancet Oncol; 2019 Mar; 20(3):436-447. PubMed ID: 30713036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of investigation intensity and treatment differences on prostate cancer survivor's physical symptoms, psychological well-being and health-related quality of life: a two country cross-sectional study.
    Gavin AT; Donnelly D; Donnelly C; Drummond FJ; Morgan E; Gormley GJ; Sharp L
    BMJ Open; 2016 Dec; 6(12):e012952. PubMed ID: 27993906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
    Watson E; Shinkins B; Frith E; Neal D; Hamdy F; Walter F; Weller D; Wilkinson C; Faithfull S; Wolstenholme J; Sooriakumaran P; Kastner C; Campbell C; Neal R; Butcher H; Matthews M; Perera R; Rose P
    BJU Int; 2016 Jun; 117(6B):E10-9. PubMed ID: 25818406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
    Lane A; Metcalfe C; Young GJ; Peters TJ; Blazeby J; Avery KN; Dedman D; Down L; Mason MD; Neal DE; Hamdy FC; Donovan JL;
    BJU Int; 2016 Dec; 118(6):869-879. PubMed ID: 27415448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining relationships between age at diagnosis and health-related quality of life outcomes in prostate cancer survivors.
    Kurian CJ; Leader AE; Thong MSY; Keith SW; Zeigler-Johnson CM
    BMC Public Health; 2018 Aug; 18(1):1060. PubMed ID: 30139347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
    Hoffman RM; Lo M; Clark JA; Albertsen PC; Barry MJ; Goodman M; Penson DF; Stanford JL; Stroup AM; Hamilton AS
    J Clin Oncol; 2017 Jul; 35(20):2306-2314. PubMed ID: 28493812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.
    Darwish-Yassine M; Berenji M; Wing D; Copeland G; Demers RY; Garlinghouse C; Fagerlin A; Newth GE; Northouse L; Holmes-Rovner M; Rovner D; Sims J; Wei JT
    J Cancer Surviv; 2014 Mar; 8(1):121-30. PubMed ID: 24214413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
    Harrison S; Tilling K; Turner EL; Lane JA; Simpkin A; Davis M; Donovan J; Hamdy FC; Neal DE; Martin RM
    Cancer Causes Control; 2016 Dec; 27(12):1465-1474. PubMed ID: 27830401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata).
    Nguyen-Nielsen M; Møller H; Tjønneland A; Borre M
    Cancer Epidemiol; 2020 Feb; 64():101623. PubMed ID: 31760356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life by human immunodeficiency virus status in a cross-sectional survey of gay and bisexual prostate cancer survivors.
    Polter EJ; Wheldon CW; Rosser BRS; Kohli N; Capistrant BD; Kapoor A; Konety B; Mitteldorf D; Ross M; Talley KMC; Terveen L; West W; Wright MM
    Psychooncology; 2019 Dec; 28(12):2351-2357. PubMed ID: 31518042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
    Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
    Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.